GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Capex-to-Operating-Income

Revvity (Revvity) Capex-to-Operating-Income : 0.40 (As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Revvity's Capital Expenditure for the three months ended in Mar. 2024 was $-17.84 Mil. Its Operating Income for the three months ended in Mar. 2024 was $44.12 Mil.

Hence, Revvity's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.40.


Revvity Capex-to-Operating-Income Historical Data

The historical data trend for Revvity's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Capex-to-Operating-Income Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.07 0.07 0.12 0.27

Revvity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.18 0.33 0.29 0.40

Competitive Comparison of Revvity's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, Revvity's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Revvity's Capex-to-Operating-Income falls into.



Revvity Capex-to-Operating-Income Calculation

Revvity's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-81.368) / 300.562
=0.27

Revvity's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-17.844) / 44.116
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revvity  (NYSE:RVTY) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Revvity Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Revvity's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121

Revvity (Revvity) Headlines

From GuruFocus

Q1 2023 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Revvity Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

PerkinElmer Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Revvity Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024